Table S5 from The Oncogenic FOXL2 C134W Mutation Is a Key Driver of Granulosa Cell Tumors

Table S5 from The Oncogenic FOXL2 C134W Mutation Is a Key Driver of Granulosa Cell Tumors

<p>Table S5</p>

Uloženo v:

Podrobná bibliografie
Hlavní autor:	Elena Llano (14963220) (author)
Další autoři:	Anne Laure Todeschini (14963223) (author), Natalia Felipe-Medina (14963226) (author), María D. Corte-Torres (14963229) (author), Yazmine B. Condezo (14963232) (author), Manuel Sanchez-Martin (14963235) (author), Sara López-Tamargo (14963238) (author), Aurora Astudillo (14963241) (author), Xose S. Puente (14935902) (author), Alberto M. Pendas (14963244) (author), Reiner A. Veitia (14963247) (author)
Vydáno:	2025
Témata:	Cancer Cancer Biology Molecular and Cellular Biology Carcinogenesis Animal models of carcinogenesis Genome Biology Comparative transcriptomics Gynecological Cancers Ovarian cancer
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Podobné jednotky

Table S2 from The Oncogenic FOXL2 C134W Mutation Is a Key Driver of Granulosa Cell Tumors
Autor: Elena Llano (14963220)
Vydáno: (2025)

Table S3 from The Oncogenic FOXL2 C134W Mutation Is a Key Driver of Granulosa Cell Tumors
Autor: Elena Llano (14963220)
Vydáno: (2025)

table s1 from The Oncogenic FOXL2 C134W Mutation Is a Key Driver of Granulosa Cell Tumors
Autor: Elena Llano (14963220)
Vydáno: (2025)

table s4 from The Oncogenic FOXL2 C134W Mutation Is a Key Driver of Granulosa Cell Tumors
Autor: Elena Llano (14963220)
Vydáno: (2025)

Supplemental Table S3 from Spatial Transcriptomic Analysis of Ovarian Cancer Precursors Reveals Reactivation of IGFBP2 during Pathogenesis
Autor: Yeh Wang (14964041)
Vydáno: (2025)

Supplemental Table S4 from Spatial Transcriptomic Analysis of Ovarian Cancer Precursors Reveals Reactivation of IGFBP2 during Pathogenesis
Autor: Yeh Wang (14964041)
Vydáno: (2025)

Table S1 from TONSL Is an Immortalizing Oncogene and a Therapeutic Target in Breast Cancer
Autor: Aditi S. Khatpe (15293176)
Vydáno: (2025)

Table S10 from TONSL Is an Immortalizing Oncogene and a Therapeutic Target in Breast Cancer
Autor: Aditi S. Khatpe (15293176)
Vydáno: (2025)

Table S11 from TONSL Is an Immortalizing Oncogene and a Therapeutic Target in Breast Cancer
Autor: Aditi S. Khatpe (15293176)
Vydáno: (2025)

Table S12 from TONSL Is an Immortalizing Oncogene and a Therapeutic Target in Breast Cancer
Autor: Aditi S. Khatpe (15293176)
Vydáno: (2025)

Table S13 from TONSL Is an Immortalizing Oncogene and a Therapeutic Target in Breast Cancer
Autor: Aditi S. Khatpe (15293176)
Vydáno: (2025)

Table S14 from TONSL Is an Immortalizing Oncogene and a Therapeutic Target in Breast Cancer
Autor: Aditi S. Khatpe (15293176)
Vydáno: (2025)

Table S15 from TONSL Is an Immortalizing Oncogene and a Therapeutic Target in Breast Cancer
Autor: Aditi S. Khatpe (15293176)
Vydáno: (2025)

Table S2 from TONSL Is an Immortalizing Oncogene and a Therapeutic Target in Breast Cancer
Autor: Aditi S. Khatpe (15293176)
Vydáno: (2025)

Table S3 from TONSL Is an Immortalizing Oncogene and a Therapeutic Target in Breast Cancer
Autor: Aditi S. Khatpe (15293176)
Vydáno: (2025)

Table S4 from TONSL Is an Immortalizing Oncogene and a Therapeutic Target in Breast Cancer
Autor: Aditi S. Khatpe (15293176)
Vydáno: (2025)

Table S9 from TONSL Is an Immortalizing Oncogene and a Therapeutic Target in Breast Cancer
Autor: Aditi S. Khatpe (15293176)
Vydáno: (2025)

Data Sheet 1_MRI-based radiomic clustering identifies a glioblastoma subtype enriched for neural stemness and proliferative programs.csv
Autor: Zhongyi Zhang (219440)
Vydáno: (2025)

Data Sheet 2_MRI-based radiomic clustering identifies a glioblastoma subtype enriched for neural stemness and proliferative programs.pdf
Autor: Zhongyi Zhang (219440)
Vydáno: (2025)

Supplementary Figures S1-S4 from The Prognostic Effect of Immune Cell Infiltration Depends on Molecular Subtype in Endometrioid Ovarian Carcinomas
Autor: Karolin Heinze (16540724)
Vydáno: (2025)

Supplementary Tables S1-S5 from The Prognostic Effect of Immune Cell Infiltration Depends on Molecular Subtype in Endometrioid Ovarian Carcinomas
Autor: Karolin Heinze (16540724)
Vydáno: (2025)

Image 5_Exploratory spatial transcriptomic profiling of peritumoral Th2 immune polarization in HPV-positive oropharyngeal cancer.jpeg
Autor: Naohiro Wakisaka (407153)
Vydáno: (2025)

Table 1_Exploratory spatial transcriptomic profiling of peritumoral Th2 immune polarization in HPV-positive oropharyngeal cancer.xlsx
Autor: Naohiro Wakisaka (407153)
Vydáno: (2025)

Image 4_Exploratory spatial transcriptomic profiling of peritumoral Th2 immune polarization in HPV-positive oropharyngeal cancer.jpeg
Autor: Naohiro Wakisaka (407153)
Vydáno: (2025)

Image 2_Exploratory spatial transcriptomic profiling of peritumoral Th2 immune polarization in HPV-positive oropharyngeal cancer.jpeg
Autor: Naohiro Wakisaka (407153)
Vydáno: (2025)

Image 3_Exploratory spatial transcriptomic profiling of peritumoral Th2 immune polarization in HPV-positive oropharyngeal cancer.jpeg
Autor: Naohiro Wakisaka (407153)
Vydáno: (2025)

Image 1_Exploratory spatial transcriptomic profiling of peritumoral Th2 immune polarization in HPV-positive oropharyngeal cancer.jpeg
Autor: Naohiro Wakisaka (407153)
Vydáno: (2025)

44d_RNAseq_data from A Pro-Regenerative Environment Triggers Premalignant to Malignant Transformation of Senescent Hepatocytes
Autor: Anna Wuestefeld (14963115)
Vydáno: (2025)

Supplementary Table S1 from Estrogen-DNA Adducts and Breast Cancer Risk in Premenopausal Asian Women
Autor: Ching-Hung Lin (15110557)
Vydáno: (2025)

Supplementary Table 1 from Spatial Transcriptomics Depict Ligand–Receptor Cross-talk Heterogeneity at the Tumor-Stroma Interface in Long-Term Ovarian Cancer Survivors
Autor: Sammy Ferri-Borgogno (15307295)
Vydáno: (2025)

Supplementary Table 2 from Spatial Transcriptomics Depict Ligand–Receptor Cross-talk Heterogeneity at the Tumor-Stroma Interface in Long-Term Ovarian Cancer Survivors
Autor: Sammy Ferri-Borgogno (15307295)
Vydáno: (2025)

Supplementary Table 3 from Spatial Transcriptomics Depict Ligand–Receptor Cross-talk Heterogeneity at the Tumor-Stroma Interface in Long-Term Ovarian Cancer Survivors
Autor: Sammy Ferri-Borgogno (15307295)
Vydáno: (2025)

Supplementary Table 4 from Spatial Transcriptomics Depict Ligand–Receptor Cross-talk Heterogeneity at the Tumor-Stroma Interface in Long-Term Ovarian Cancer Survivors
Autor: Sammy Ferri-Borgogno (15307295)
Vydáno: (2025)

Figure S1 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
Autor: Martina S.J. McDermott (15206951)
Vydáno: (2025)

Figure S2 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
Autor: Martina S.J. McDermott (15206951)
Vydáno: (2025)

Figure S3 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
Autor: Martina S.J. McDermott (15206951)
Vydáno: (2025)

Figure S4 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
Autor: Martina S.J. McDermott (15206951)
Vydáno: (2025)

Figure S5 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
Autor: Martina S.J. McDermott (15206951)
Vydáno: (2025)

Figure S6 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
Autor: Martina S.J. McDermott (15206951)
Vydáno: (2025)

Figure S7 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
Autor: Martina S.J. McDermott (15206951)
Vydáno: (2025)

Cannot write session to /tmp/vufind_sessions/sess_bmocucjn18bet97m42h1kuhjnh